Cargando…

Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase

Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs or dialysis-dependent end-stage renal disease. The study aims to compare prophylaxis with fondaparinux (Fund) vs. treatment with alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male m...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Bakky, Mohamed S., Aldakhili, Anas S. A., Ali, Hussein M., Babiker, Ali Y., Alhowail, Ahmad H., Mohammed, Salman A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383028/
https://www.ncbi.nlm.nih.gov/pubmed/37513824
http://dx.doi.org/10.3390/ph16070910
_version_ 1785080805988499456
author Abdel-Bakky, Mohamed S.
Aldakhili, Anas S. A.
Ali, Hussein M.
Babiker, Ali Y.
Alhowail, Ahmad H.
Mohammed, Salman A. A.
author_facet Abdel-Bakky, Mohamed S.
Aldakhili, Anas S. A.
Ali, Hussein M.
Babiker, Ali Y.
Alhowail, Ahmad H.
Mohammed, Salman A. A.
author_sort Abdel-Bakky, Mohamed S.
collection PubMed
description Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs or dialysis-dependent end-stage renal disease. The study aims to compare prophylaxis with fondaparinux (Fund) vs. treatment with alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male mice were equally divided randomly into six groups of control, Cis, Alt, and Cis + Alt groups receiving normal saline for 10 days. All four groups except for the control received Cis (30 mg/kg, i.p.) on day 7, and 6 h later, both the Alt groups received Alt (0.9 mg/kg, i.v.). The animal groups Fund and Fund + Cis received Fund (5 mg/kg, i.p.) for 10 days, and the Fund + Cis group on day 7 received Cis. All the animal groups were euthanized 72 h after the Cis dose. The Fund + Cis group showed significantly increased expression levels of platelet count, retinoid X receptor alpha (RXR-α) and phosphorylated Akt (p-Akt) in addition to decreased levels of urea, blood urea nitrogen (BUN), uric acid, white blood cells (WBCs), red blood cells (RBCs), relative kidney body weight, kidney injury score, glucose, prothrombin (PT), A Disintegrin And Metalloproteinases-10 (ADAM10), extracellular matrix deposition, protease-activated receptor 2 (PAR-2), and fibrinogen expression when compared to the Cis-only group. Meanwhile, the Cis + Alt group showed increased caspase-3 expression in addition to decreased levels of urea, BUN, uric acid, WBCs, RBCs, glucose, platelet count and PT expression with a marked decrease in PAR-2 protein expression compared to the Cis group. The creatinine levels for both the Fund + Cis and Cis + Alt groups were found to be comparable to those of the Cis-only group. The results demonstrate that the coagulation system’s activation through the stimulation of PAR-2 and fibrinogen due to Cis-induced ADAM10 protein expression mediated the apoptotic pathway, as indicated by caspase-3 expression through the p-Akt pathway. This is normally accompanied by the loss of RXR-α distal and proximal tubules as lipid droplets. When the animals were pre-treated with the anticoagulant, Fund, the previous deleterious effect was halted while the fibrinolytic agent, Alt, most of the time failed to treat Cis-induced toxicity.
format Online
Article
Text
id pubmed-10383028
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103830282023-07-30 Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase Abdel-Bakky, Mohamed S. Aldakhili, Anas S. A. Ali, Hussein M. Babiker, Ali Y. Alhowail, Ahmad H. Mohammed, Salman A. A. Pharmaceuticals (Basel) Article Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs or dialysis-dependent end-stage renal disease. The study aims to compare prophylaxis with fondaparinux (Fund) vs. treatment with alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male mice were equally divided randomly into six groups of control, Cis, Alt, and Cis + Alt groups receiving normal saline for 10 days. All four groups except for the control received Cis (30 mg/kg, i.p.) on day 7, and 6 h later, both the Alt groups received Alt (0.9 mg/kg, i.v.). The animal groups Fund and Fund + Cis received Fund (5 mg/kg, i.p.) for 10 days, and the Fund + Cis group on day 7 received Cis. All the animal groups were euthanized 72 h after the Cis dose. The Fund + Cis group showed significantly increased expression levels of platelet count, retinoid X receptor alpha (RXR-α) and phosphorylated Akt (p-Akt) in addition to decreased levels of urea, blood urea nitrogen (BUN), uric acid, white blood cells (WBCs), red blood cells (RBCs), relative kidney body weight, kidney injury score, glucose, prothrombin (PT), A Disintegrin And Metalloproteinases-10 (ADAM10), extracellular matrix deposition, protease-activated receptor 2 (PAR-2), and fibrinogen expression when compared to the Cis-only group. Meanwhile, the Cis + Alt group showed increased caspase-3 expression in addition to decreased levels of urea, BUN, uric acid, WBCs, RBCs, glucose, platelet count and PT expression with a marked decrease in PAR-2 protein expression compared to the Cis group. The creatinine levels for both the Fund + Cis and Cis + Alt groups were found to be comparable to those of the Cis-only group. The results demonstrate that the coagulation system’s activation through the stimulation of PAR-2 and fibrinogen due to Cis-induced ADAM10 protein expression mediated the apoptotic pathway, as indicated by caspase-3 expression through the p-Akt pathway. This is normally accompanied by the loss of RXR-α distal and proximal tubules as lipid droplets. When the animals were pre-treated with the anticoagulant, Fund, the previous deleterious effect was halted while the fibrinolytic agent, Alt, most of the time failed to treat Cis-induced toxicity. MDPI 2023-06-21 /pmc/articles/PMC10383028/ /pubmed/37513824 http://dx.doi.org/10.3390/ph16070910 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abdel-Bakky, Mohamed S.
Aldakhili, Anas S. A.
Ali, Hussein M.
Babiker, Ali Y.
Alhowail, Ahmad H.
Mohammed, Salman A. A.
Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title_full Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title_fullStr Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title_full_unstemmed Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title_short Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
title_sort evaluation of cisplatin-induced acute renal failure amelioration using fondaparinux and alteplase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383028/
https://www.ncbi.nlm.nih.gov/pubmed/37513824
http://dx.doi.org/10.3390/ph16070910
work_keys_str_mv AT abdelbakkymohameds evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase
AT aldakhilianassa evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase
AT alihusseinm evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase
AT babikeraliy evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase
AT alhowailahmadh evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase
AT mohammedsalmanaa evaluationofcisplatininducedacuterenalfailureameliorationusingfondaparinuxandalteplase